Skip to main content

Digital transformation in life sciences

How pharma and medtech can shift from doing digital to being digital

Digital transformation is no longer a buzzword—it’s a strategic imperative. How can life sciences companies advance their capabilities and take a more holistic view of their digital strategies?

Tune in to Season 3: Moving from doing digital to being digital in life sciences

Digital transformation might be the buzzword of the day, but for life sciences companies it is becoming a critical imperative to succeed in a changing business environment. This season of Tales of Transformation explores digital transformation in life sciences and the challenges and opportunities companies face in moving from doing digital to being digital.

Unleash digital opportunities

Opportunities for digital transformation are available throughout a life sciences organisation, from improving finance, supply chain and manufacturing operations, to developing new products and services, to engaging differently with customers and patients.

While many life sciences companies have been exploring the opportunities that digital technologies can offer, many have yet to make consistent, sustained and bold moves to take advantage of the new capabilities. Only about 20 percent of biopharma companies are digitally maturing. Digitally maturing companies differ from those in the earlier stages of digital maturity in the way they apply digital, scale learnings, collaborate and facilitate change. More digitally mature companies also implement digital initiatives in stages, establishing pilots and taking a measured approach to scaling initiatives based on lessons learnt.

Realising opportunities from a digital transformation requires an overall strategy: A digital foundation that can take advantage of emerging technologies—such as analytics, cognitive intelligence, blockchain, cloud, digital reality—harness data and scale across the organisation; a culture of collaboration and experimentation; and supportive leadership.

A framework to guide your digital transformation

Digital transformation offers biopharma and medtech companies opportunities to execute efficiently, engage effectively and innovate new products and services.

Execute Efficiently

Digitise and rationalise processes to drive efficiencies and cost savings and develop a digital culture that enables new ways of thinking and capabilities.

Engage Effectively

Drive a new enegagement model that creates and delivers targeted interactions that address customer/patient/employee needs and fosters loyal relationships.

Innovate New products and services

Catalyse the development of products, services and new business models to drive value for customers using data and innovative platforms.

Developing and delivering a digital strategy is not an easy task. And there’s a tendency to manage digital initiatives in ways that take the form of projects or are limited to activities within a given division or function. Life sciences companies that want to move away from that tendency need to develop a digital DNA by which their digital activities, people, culture and structure are aligned with the organisation’s broad ambition. That goal requires seeing differently, thinking differently and doing differently across the organisation.

Weighing the risk of digital transformation

Even as life sciences companies develop, implement and refine their digital strategies, concerns about risks are likely to arise. Can digital systems work well enough to ensure the safety of products, security of consumers’ and company information and compliance with regulatory requirements? These concerns can become a barrier to change in some organisations or parts of the organisation. However, organisations should acknowledge that risk is inherent in digital transformation and take steps to address it rather than delay the opportunities digital can bring.

How Deloitte can help build your digital strategy and capabilities

There isn’t a one-size approach to digital transformation. Some companies may pursue a top-down approach. Others may opt for a bottom-up or even horizonal approach focussed on a key business problem or technology. Regardless of the approach, we can help you create a digital view that illuminates new business opportunities and creative ways of solving problems.

Not only is Deloitte at the forefront of digital transformation across industries, we have deep, specific, hands-on experience in biopharma, medtech and the health care ecosystem.

We can work collaboratively with you to define your strategy, develop an architecture aligned to business objectives and design an operating model that enables seamless collaboration and connectivity—internally and externally—all while helping your organisation bring its own digital DNA to life.

If done correctly, digital transformation can help you more effectively use data for making decisions on how to run the existing business and position the organisation for the future.

Connect and converge with ConvergeHEALTH

In today’s market, truly actionable insights are derived from a combination of real-world information, evidence and experience—not just data. How can you maximise the value of your data?

Learn how ConvergeHEALTH platforms can help you better manage evidence and engage patients.

Digital transformation in action: Client case studies

See how we created a self-service cognitive platform to help a biopharma company streamline their clinical trial data.

Watch how a pharmaceutical company leveraged digital capabilities—with our help—to customize 1:1 engagement with health care providers.

Takeda, a leading global R&D pharmaceutical company, was seeking to improve the accuracy of its prediction models for various disease states. They believed Artificial intelligence (AI) could be a powerful tool in this effort but needed to create a model that could prove their hypothesis. To achieve their goals, they enlisted the help of Deloitte to create a cloud solution.

Using a small, proven real-world data set on Treatment-Resistant Depression and NASH, a severe form of hepatitis, Takeda and Deloitte deployed a scalable, AWS cloud-based machine learning solution called Deep Miner to rapidly test predictive models. Cloud delivered—accelerating the development of the solution and delivering insights faster. Just as Takeda hoped, the solution generated unprecedented insights their teams can now apply across a range of data to refine drug development and planning of clinical trials.

The model proved highly accurate in its predictions, outperforming previously tested traditional analyses. Accuracy jumped almost 40 percent, which will inform drug development, product pipeline planning, and help Takeda to appreciate the unmet needs of patients and improve patient outcomes. And, the cloud made it happen. Fast.

Download the PDF

Did you find this useful?

Thanks for your feedback

If you would like to help improve further, please complete a 3-minute survey